Literature DB >> 15849772

Reversible drug-induced interstitial pneumonitis following imatinib mesylate therapy.

Jay Rajda, Pradyumna D Phatak.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15849772     DOI: 10.1002/ajh.20319

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


× No keyword cloud information.
  7 in total

Review 1.  Pulmonary toxicities from targeted therapies: a review.

Authors:  Nicholas A Barber; Apar Kishor Ganti
Journal:  Target Oncol       Date:  2011-11-11       Impact factor: 4.493

2.  A case of chronic myeloid leukemia with eosinophilic interstitial pneumonitis after administration of imatinib mesylate for 11 months.

Authors:  Koichiro Suemori; Hiroshi Fujiwara; Seiichiro Watanabe; Taichi Azuma; Masaki Yasukawa
Journal:  Int J Hematol       Date:  2010-11-26       Impact factor: 2.490

Review 3.  Infiltrative lung diseases: complications of novel antineoplastic agents in patients with hematological malignancies.

Authors:  Bobbak Vahid; Paul E Marik
Journal:  Can Respir J       Date:  2008 May-Jun       Impact factor: 2.409

Review 4.  Anticancer therapy and lung injury: molecular mechanisms.

Authors:  Li Li; Henry Mok; Pavan Jhaveri; Mark D Bonnen; Andrew G Sikora; N Tony Eissa; Ritsuko U Komaki; Yohannes T Ghebre
Journal:  Expert Rev Anticancer Ther       Date:  2018-07-23       Impact factor: 4.512

5.  Interstitial pneumonitis in a patient with chronic myeloid leukemia.

Authors:  Ahmet Emre Eşkazan; Ayşe Salihoğlu; Serdar Erturan; Teoman Soysal
Journal:  Turk J Haematol       Date:  2013-12-05       Impact factor: 1.831

Review 6.  European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia.

Authors:  J L Steegmann; M Baccarani; M Breccia; L F Casado; V García-Gutiérrez; A Hochhaus; D-W Kim; T D Kim; H J Khoury; P Le Coutre; J Mayer; D Milojkovic; K Porkka; D Rea; G Rosti; S Saussele; R Hehlmann; R E Clark
Journal:  Leukemia       Date:  2016-04-28       Impact factor: 11.528

7.  Nilotinib-induced interstitial lung disease.

Authors:  Se-Il Go; Won Sup Lee; Gyeong-Won Lee; Jung Hun Kang; Myung Hee Kang; Jeong-Hee Lee; Hoon-Gu Kim
Journal:  Int J Hematol       Date:  2013-07-23       Impact factor: 2.490

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.